Illumina (NASDAQ: ILMN) spun off liquid biopsy company GRAIL a few years ago. But the big genomic sequencing pioneer now wants GRAIL back. However, there’s a potential wrinkle that could derail Illumina’s plans. In this Motley Fool Live video recorded on March 31, Motley Fool contributors Keith Speights and Brian Orelli discuss whether Illumina’s quest to acquire GRAIL could ultimately fail.
Get breaking news delivered straight into your inbox